#
May 20, 2020
Dr. Marusak provides an update on progress so far.
#
May 19, 2020
Dyne to evaluate therapies targeting genetic cause of FSHD under agreement with international research organization University of Mons
#
May 13, 2020
Fulcrum amends their Phase 2b trial, ReDUX4, to extend the trial from 24 to 48 weeks, adds an interim analysis for subjects who underwent their 16-week biopsy as originally planned, and adds a 36-week biopsy for patients who cannot undergo their 16-week biopsy.
#
Apr 26, 2020
Those living with FSHD know firsthand what it's like to see the world through a changing lens. Recently, Chris Carrino shared some words of encouragement on the Brooklyn Nets website and social media outlets.
#
Apr 17, 2020
Darina Šikrová provides a progress update of her work on using a novel genome editing tool to target DUX4.
#
Apr 2, 2020
As a result of the suspension of clinical-trial activity by a number of the Company’s clinical trial sites stemming from the pandemic, the Company is currently assessing the impact to the ReDUX4 clinical trial.
#
Mar 26, 2020
GiveBIG for Seattle. Friends of FSH Research is suggesting you donate to other non-profits for GiveBIG this year.
#
Mar 10, 2020
Latest progress from Yosuke Hiramuki.
#
Feb 7, 2020
Our latest call for research proposals.
#
Feb 3, 2020
Dr. Kyba provides a brief update on our help with recruiting study participants.
#
Feb 1, 2020
Slideshow on molecular mechanisms of DUX4 which was presented at the Wellstone Research Update 2020 by Danielle Hamm PhD.
#
Feb 1, 2020
Slideshow on aberrant translation which was presented at the Wellstone Research Update 2020 by Sujatha Jagannathan PhD.
#
Jan 31, 2020
Slideshow on epigenetics which was presented at the Wellstone Research Update 2020 by Peter Jones PhD.
#
Jan 30, 2020
Fulcrum Therapeutics announced that the FDA has granted Orphan Drug Designation to losmapimod, a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor.
#
Jan 28, 2020
Rashnonajad provides the initial progress update showing efficiently reduced DUX4 mRNA and consequently DUX4 protein in FSHD cells.
#
Jan 9, 2020
The Friends of FSH Research is partnering with the FSHD Society on a landmark Voice of the Patient Forum for Drug Development.
#
Dec 15, 2019
Researchers at the University of Washington and Seattle Children’s Hospital are seeking volunteers for a study on FSHD.
#
Dec 9, 2019
Sachiko Homma provides the final update on DUX4's apparent affect on muscle degradation.
#
Nov 25, 2019
Wellstone FSHD Fellowship recipient Danielle Hamm provides an update on the first six months of progress.
#
Nov 24, 2019
The funding provided by Friends of FSH Research and the Carrino Foundation has supported Dr. Amy Campbell, a dedicated professional highly skilled in FSHD research who oversees the completion of high-impact studies on FSHD and provides scientific and technical oversight for graduate students, postdoctoral fellows, and collaborators seeking to initiate and/or advance projects in FSHD.